AstraZeneca (AZN.US) Announces Positive FLAURA2 Study Results Osimitinib Joint Program Helps Improve Lung Cancer OS

The Zhitong Finance App learned that on July 21, AstraZeneca (AZN.US) announced positive results in the final overall survival (OS) analysis of the phase III FLAURA2 study: in first-line treatment of locally advanced or metastatic epidermal growth factor receptor (EGFRM) non-small cell lung cancer (NSCLC) patients, osidinib combined with pemetrexed and platinum chemotherapy showed significant statistical and clinical improvements in key secondary endpoint OS compared with ositinib monotherapy.

The final OS analysis results were consistent with the previously reported mid-term OS results, confirming the continued survival benefit, and were based on previously published primary endpoint data — this data showed the longest median progression-free survival (PFS) in the context of this treatment.

“The goal of treating lung cancer is not only to prolong survival but also to improve the patient experience, especially in first-line treatment, because treatment can last a long time and many patients still need to maintain an active lifestyle,” said Pasi A. Jänne, the lead researcher in the Flaura2 trial. These positive results support osidinib (either as a single agent or in combination with chemotherapy) as the standard first-line treatment for patients with advanced EGFR mutant lung cancer, and reinforce the significant benefits of this combination therapy in the current clinical environment. Considering that the FLAURA2 trial did not place any restrictions on subsequent treatment options after disease progression, the observed survival benefits are particularly impressive.”